Systemic active immunotherapy is shifting from the middle ages to a renaissance period G. Mathé Editorial Pages: 149 - 152
Immunotherapy of neoplastic diseases with neuraminidase: Contradictions, new aspects, and revised concepts H. H. SedlacekF. R. Seiler General Review Pages: 153 - 163
T and B lymphocyte populations of tumor-bearing mice treated with 1,3-bis(chloroethyl)-1-nitrosourea (BCNU) or pyran W. A. StylosM. A. ChirigosP. J. Lyng Original Articles Pages: 165 - 172
Cytotoxicity of adherent cells associated with some human tumours and lung tissues B. M. Vose Original Articles Pages: 173 - 179
Canine osteosarcoma: Results of amputation with and without adjuvant immunotherapy P. L. WeidenR. StorbT. C. Graham Original Articles Pages: 181 - 186
The use of antifibrin antibodies for the destruction of tumor cells F. H. LeeS. FujimotoA. H. Sehon Original Articles Pages: 187 - 193
The use of antifibrin antibodies for the destruction of tumor cells F. H. LeeS. FujimotoA. H. Sehon Original Articles Pages: 195 - 200
The use of antifibrin antibodies for the destruction of tumor cells F. H. LeeI. BercziA. H. Sehon Original Articles Pages: 201 - 206
Delayed tumor growth caused by a combined treatment with BCG and Pseudomonas aeruginosa N. KigerJ. SchulzG. Mathé Short Communication Pages: 207 - 210
In vivo immunostimulation by tuftsin I. FlorentinM. Bruley-RossetG. Mathé Short Communication Pages: 211 - 216
